

SUBMISSION UNDER MPEP 609 D

Application Number 10/596,732
Filing Date 06/22/2006
First Named Inventor Goyvaerts, Nicolaas
Group Art Unit 1625
Examiner Name OWENS, Amelia A.
Attorney Docket Number TIP-0056USPCT

Page 1 of 1

U.S. PATENT DOCUMENTS U.S. Patent Document Pages, Columns, Lines Name of Patentee or Applicant Examiner Cite Kind Code where relevant passages or relevant figures appear of Cited Document Initials No.1 Number (if known) FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages or relevant figures Name of Patentee or Evaminer Cite Applicant of Cited Document Initials Office³ Number⁴ KindCode⁵ appear OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), T2 Cite No. volume-issue number(s), publisher, city and/or country where published 's Initials* International Search Report, International Application Number PCT/EP2004/053692, Date of Mailing of International Search Report, May 2, 2005.

Examiner Date Signature Considered



PTC/SB/08A (06-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a velid OMB control number.

Attorney Docket Number

05/22/1997

Application Number 10/596,732
Filing Date 06/22/2006
First Named Inventor Goyvaerts, Nicolaas
Group Art Unit 1625
Examiner Name OWENS, Amelia A.

TIP-0056USPCT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

WO 97/18205

U.S. PATENT DOCUMENTS							
		U.S. Patent Do	cument		Date of Publication	Pages, Columns, Lines,	
Exeminer Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear	

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, where relevant of Cited Document Name of Patentee or Examine Cite passages or relevant figures appear mm-dd-ww Applicant of Cited Document Initials Office³ Number⁴ KindCode⁵ No.1 wo 98/07685 Gilead Sciences, Inc. 02-26-1998 wo 99/48885 A1 Glaxo Group Limited 09-30-1999 MO 99/67417 A2 Dept. of Health & Human 12-29-1999 Services, United States of America wo 01/12599 A Samphully Pharm Co., Ltd. 02-22-2001 wo 01/46120 A1 Aeojet Fine Chemicals LLC 06-28-2001 wo 02/092595 A1 Tibotec Pharmaceuticals, Ltd. 11-21-2002 wo 03/106461 Tibotec Pharmaceuticals, Ltd. 12-24-2003 03/057665 Ajinomoto Co., Inc. & English 07-17-2003 wo 03/022853 A1 Tibotec Pharmaceuticals, Ltd. 03-20-2003 WO 94/05639 Vertex Pharmaceuticals Inc. 03-17-1994 wo 95/06030 G.D Searte & Co. 03/02/1995 wo 96/28463 G.D Searle & Co. 00/10/1006 wo 96/28464 G.D. Searle & Co 00/10/1006

Examiner	Date	
Cignotum	Considered	

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Unique obtation designation number: Siee attached Kinds of U.S. Patient Documents. Exter Office that issued the document, by the two-letter code (WIPO Standard ST-3), 476-1, pageness patient documents, the indication of the year of the regin of the Empirer must precisel the sential number of the patient document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Application is to place a check mark here it families herosance Translation is attached.

G.D. Searle & Co.

Burdon Hour Statement: This form is astimated to bake 20 hours to complete. Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete the form should be sent to the Clieb Homatico Officer, U.S. Patent and Trademark. Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, U.S. 2313-1450



PTO/SB/98A (08-00)
Approved for use through 10/31/2002, OMB 9651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

a conection of Prioritiation stress it disprays a valid OMB control flumber.						
Application Number	10/596,732					
Filing Date	06/22/2006					
First Named Inventor	Goyvaerts, Nicolaas					
Group Art Unit	1625					
Examiner Name	OWENS, Amelia A.					
Attorney Docket Number	TIP-0056USPCT					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's nitials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
		Bodanszky, M., Principles of Peptide Synthesis, 1 st and 2 st revised edition, 1984 and 1993, Springer-Verlag, New York.	
		Cerfontain, Hans., Machanistic Aspects in Aromatic Sulfonation and Desulfonation, 1968, Interscience Publishers, New York	
		CROSS L.C., et al., "Rules for The Nomenclature of Organic Chemistry, Section E: Sterochemistry,", Pure & Appl. Chem., 1976, Vol. 45, pages 11-30.	
		Fieser et al., Reagents for Organic Synthesis, 1994, Volume 17, John Wiley & Sons.	
		GHOSH, A.K. et al., "Nonpeptidal P2 Ligands for HIV Protease Inhibitores: Structure-Based Design Synthesis and Biological Evaluation.", <u>Journal of Medicinal Chemistry</u> , 1996, Vol. 39, pages 3278-3290, American Chemical Society, Washinston, US, XP002 193356.	
		GHOSH, A.K. et al., "Potent HIV Protease Inhibitors Incorporating High-Affinity P2-ligands and (R)- Hydroxyathytamino/Sulfonamide Societies", <u>Bioorpanic & Medicinal Chemistry Letters</u> , March 17, 1996, Vol. 8, No. 6, pages 697-690, Oxford, GB, XPOO-136945.	
		Gilbert, Everett, E., Sulfonation and Related Reactions, 1977, Interscience Publishers, New York.	
		GREENE T. W., et al., "Protective Groups in Organic Synthesis", 2 rd edition, T.W. Greene & P.G.M.Wutz, 1991, Wiley Interscience.	
		KIM, B.M. et al., "Synthesis of a Chiral Azirdine Derivatives a Versatle Intermediate for HIV Protease Inhibitors.", Organic Letters, 2001, Vol. 3, No. 15, 2001, pages. 2349-2351, XP0001179485. MARCH, J., "Advanced Organic Chemistry", 3 rd edition, 1985, pages 1038-1039.	
		McManus, S.P. et al., "The Synthesis of Aminoalcohols From Epoxides and Amonia.", Synthetic Communications, 1973, Vol. 3, No. 3, pages 177-180.	
	l	Paquette, Leo A., Encyclopedia of Reagents for Organic Synthesis, 1995, John Wiley & Sons, New York, US.	
		Stewart, J.M. et al., <u>Solid Phase Peptide Synthesis</u> , 2 ^{rol} edition, 1984, W.H. Freeman and Company, San Franciso, CA, US.	
-	-		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to lake 2.0 hours to complete. Time will vary depending upon the needs of the individual cases Any comments on the amount of time you are expained to complete the fem should be sent to the Challe Homestico Office, V. S. Palent and Trademac Office, Washington, DC 2023.1. S. Palent and Trademac Office, Washington, DC 2023.1. S. Palent and Trademac Office, Washington, DC 2023.1. S. Palent and Challe S. P

s Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
a a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many shoets os necessary)

Sheet 1 of 3

			U.S. PATENT DOCUMENTS		
	U.S. Patent Do	cument		D-1- 40 45 -5	. Pages, Columns, Lines,
Cite No.1	Number	Kind Code ² (if known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages o relevant figures appear
_					
	6248775	B1	G.D. Searle & Co.	06-19-2001	
	6455738	B1	Rhodia Chimie	09-24-2002	
		Cite No.1 Number	No.1 Number (if known) 6248775 B1	Cite Kind Code Name of Patentee or Applicant of Cited Document	U.S. Patent Document

FOREIGN PATENT DOCUMENTS

	Cite No.1	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials		Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T
		EP	0715618	B1	G.D. Searle & Co.	12-16-1998		Г
		EP	0774453	B1	Ajinomoto Co., Inc.	02-06-2002		Г
		EP	0754669	B1	Kaneka Corporation	10-31-2001		T
		EP	0129856	B1	Kaneka Corporation	06-16-2004		Г
		EP	1067125	B1	Kaneka Corporation	07-26-2006		Г
		EP	1081133	В1	Ajinomoto Co., Inc.	03-31-2004		
		EP	1215209	B1	Ajinomoto Co., Inc.	08-25-2004		Г
		wo	94/04492	A1	G.D. Searle & Co.	03-03-1994		Г
		wo	96/22287	A1	G.D. Searle & Co.	07-25-1996		Г
		wo	96/28418	A1	G.D. Searle & Co.	09-19-1996		Г
		wo	96/28465	A1	G.D. Searle & Co.	09-19-1996		Г
		wo	97/21685	A1	Abbott Laboratories	06-19-1997		Г

Examiner Signature	/Patricia I Morris/ (05/11/20))9) Date Considered	

EXAMINEH; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

1 Urique citation designation number: See attached Kinds of U.S. Patent Documents. Exter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4-fo. Japanese patent occuments, the indication of the year of the regit of the Empiricor must proceed the senal number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, applicating it to place a check mark here if English inaquago Translation is attached.

Burden Hour Statemert This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case, Any comments on the amount of time you are required to complete this form should be sent to the Child Hormaton Ciffice, V. B. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V. A. 22131-1450